ESC 2026丨12场Hot Line、30场LBS日程重磅发布，近20项中国研究即将亮相国际舞台！

深度解析医学证据，DeepEvidence为你支撑决策

2026年8月28日至31日，全球心血管领域的年度学术盛会——2026年欧洲心脏病学会年会（ESC 2026）将在德国慕尼黑盛大召开。本届大会共设置12个Hot Line专场及30场最新突破科学会议（Late-Breaking Science），覆盖冠心病、心力衰竭、心律失常、结构性心脏病、高血压、血脂异常、心血管影像、介入治疗、基因与细胞疗法、数字健康与人工智能等全学科领域。 值得关注的是，中国研究再次闪耀ESC舞台。本届大会中，多项由中国学者牵头或参与的重要研究入选Hot Line及Late-Breaking Science专场，涉及冠脉CT诊断、ASCVD一级预防、急性心肌梗死介入治疗、高血压管理、脂质代谢、房颤消融、肺动脉高压、心脏淀粉样变等多个热点领域。 以下是POCKETIN整理的重要日程概览，让我们一起提前了解大会亮点。

01 热线

热线 1

北京时间：8月28日 17:00~18:15

CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathyCARDIO-TTRansform研究：依普隆特森治疗转甲状腺素蛋白淀粉样变心肌病患者的疗效与安全性

马修·莫尔

SINGLE-AF: 中度卒中风险房颤患者的抗凝治疗SINGLE-AF研究：中度卒中风险房颤患者的抗凝治疗

钟浩英

POET-II: tailored duration antibiotic treatment for infectious endocarditisPOET-II研究：感染性心内膜炎的个体化抗生素疗程

亨宁·邦达尔格

ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathyACACIA-HCM研究：Aficamten治疗症状性非梗阻性肥厚型心肌病

艾哈迈德·马斯里

CMR GUIDE: 心脏磁共振引导的轻中度左心室收缩功能障碍伴ICD患者的管理CMR GUIDE研究：心脏磁共振指导的轻中度左心室收缩功能障碍伴ICD患者的管理

约瑟夫·塞尔瓦纳亚甘

 

热线 2

北京时间：8月29日 14:15~15:45

STAREE: 降低老年人事件的他汀类药物STAREE研究：他汀类药物用于减少老年人心血管事件的研究

索菲亚·宗加斯

AMUNDSEN: Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial InfarctionAMUNDSEN研究：急性心肌梗死经皮冠状动脉介入治疗前使用依洛尤单抗

吉勒·蒙塔莱斯科

TRANQUILITY: 针对高心血管风险慢性肾脏病炎症的帕西贝奇单抗（IL-6配体单抗）每月和每季度给药方案的疗效TRANQUILITY研究：帕西贝奇单抗（IL-6配体单抗）每月及每季度给药方案针对高心血管风险慢性肾脏病炎症的疗效

迪帕克·巴特

REACT - 成年生活中无症状动脉粥样硬化的患病率REACT研究：成年各年龄段无症状动脉粥样硬化的患病率

亨宁·邦达尔格

ENRICH-AF: Edoxaban in intracranial hemorrhage survivors with atrial fibrillationENRICH-AF研究：艾多沙班用于伴房颤的颅内出血存活者

阿什坎·绍马内什

DAN-RSV: RSVpreF疫苗用于预防心肺相关住院DAN-RSV研究：RSVpreF疫苗用于预防心肺相关住院

托尔·比林-索伦森

 

热线 3

北京时间：8月29日 17:00~18:15

LIBREXIA ACS: Milvexian after recent ACSLIBREXIA ACS研究：近期急性冠脉综合征后使用米尔维先

菲利普·加布里埃尔·斯特

高级：STEMI患者在 primary PCI 时省略阿司匹林PREMIUM研究：STEMI患者直接PCI术中省略阿司匹林

中泽龙也

SWITCH SWEDEHEART - 从替格瑞洛转换为普拉格雷在ACS患者中的研究SWITCH SWEDEHEART研究：急性冠脉综合征患者从替格瑞洛转换为普拉格雷

埃尔米尔·奥梅罗维奇

A-CLOSE: 氯吡格雷 vs. 延长DAPT在高危PCI术后的比较A-CLOSE研究：高危PCI术后氯吡格雷 vs. 延长DAPT

金炳锡

埃皮道鲁斯埃皮道鲁斯研究

康斯坦丁诺斯·D·里扎斯

 

热线 4

北京时间：8月29日 22:15~23:15

PRESC1SE-MI: 安全性和疗效的ESC 0/1小时算法PRESC1SE-MI研究：ESC 0/1小时算法的安全性与有效性

克里斯蒂安·尤金·穆勒

0/1小时方案与标准诊疗流程在心肌梗死中的表现比较：系统综述与个体参与者数据荟萃分析0/1小时方案与标准诊疗流程在心肌梗死中的表现比较：系统综述与个体参与者数据荟萃分析

贾斯珀·布丁豪斯

AIR-STEMI试验：功能学冠状动脉造影在STEMI中的应用AIR-STEMI研究：功能学冠状动脉造影在STEMI中的应用

西蒙娜·比萨格利亚

TARGET-CTCA - 急性胸痛中的肌钙蛋白用于指导CTCATARGET-CTCA研究：急性胸痛中肌钙蛋白用于指导CTCA

尼古拉斯·米尔斯

 

热线 5

北京时间：8月29日 23:30~00:35

EMAIL-HF: 通过数字化策略在心力衰竭患者中落实SGLT2抑制剂EMAIL-HF研究：通过数字化策略在心力衰竭患者中落实SGLT2抑制剂

玛丽亚姆·埃尔梅加德

Remote Exercise SWEDEHEART: a cluster randomized cross-over trial on cardiac telerehabilitationRemote Exercise SWEDEHEART研究：心脏远程康复的整群随机交叉试验

玛丽亚·巴克

ADHERE-ASCVD: 他汀依从性的自适应数字化外展干预ADHERE-ASCVD研究：针对他汀依从性的自适应数字化外展干预

安基特·巴特

VIRTUES ICD: 虚拟植入式心律转复除颤器电子健康系统和VIRTUES PM: 起搏器数字健康平台VIRTUES ICD研究：植入式心律转复除颤器的虚拟电子健康系统及VIRTUES PM研究：起搏器的数字健康平台

拉蒂卡·帕卡什

 

热线 6

北京时间：8月30日 14:15~15:50

H-HeFT: Hydralazin-Isosorbide Dinitrate in HFrEFH-HeFT研究：肼苯哒嗪-硝酸异山梨酯在HFrEF中的应用

拉尔斯·科伯

H-ISDN Meta-Analysis: Hydralazine-Isosorbide Dinitrate in HFrEFH-ISDN荟萃分析：肼苯哒嗪-硝酸异山梨酯在HFrEF中的荟萃分析

莫滕·舒

Met-HeFT: 二甲双胍与慢性心力衰竭Met-HeFT研究：二甲双胍与慢性心力衰竭

亨里克·维格斯

明LUMINARA: 一项每日一次口服松弛素激动剂治疗心力衰竭的前瞻性随机对照试验Met-HeFT荟萃分析：二甲双胍在心力衰竭和缺血性心脏病中的应用：系统综述与荟萃分析

安德斯·霍斯特普·拉森

LUMINARA: a prospective RCT of a once daily oral relaxin agonist for treating heart failureLUMINARA研究：每日一次口服松弛素激动剂治疗心力衰竭的前瞻性随机对照试验

詹姆斯·贾努齐

PADN-PH-LHD: 用于心力衰竭患者的肺动脉高压的PADNPADN-PH-LHD研究：经皮去肺动脉神经术用于心力衰竭所致肺动脉高压患者

陈绍良教授 南京医科大学附属南京医院

TIME-HF: Team-based collaborative care model in Heart FailureTIME-HF研究：心力衰竭中的团队协作式照护模式

杰蒙·潘尼亚姆卡尔

 

热线 7

北京时间：8月30日 17:00~18:15

The POPular ACE TAVI trial: routine or selective protamine administration after TAVI?POPular ACE TAVI研究：TAVI术后常规还是选择性给予鱼精蛋白？

克里斯蒂安·奥维登

TAVI PCI: 经导管主动脉瓣植入术和经皮冠状动脉介入治疗TAVI PCI研究：经导管主动脉瓣植入术与经皮冠状动脉介入治疗

芭芭拉·伊丽莎白·施塔利

TRIC-I-HF: Tricuspid Intervention in Heart FailureTRIC-I-HF研究：心力衰竭中的三尖瓣介入治疗

约尔格·豪斯莱德

ACASA-TAVI : TAVI术后的抗血栓治疗ACASA-TAVI研究：TAVI术后的抗血栓治疗

奥文·H·莱

NOTION-4. TAVI术后亚临床瓣叶血栓形成。NOTION-4研究：TAVI术后亚临床瓣叶血栓形成

特罗尔斯·霍伊萨尔·约根森

 

热线 8

北京时间：8月30日 22:15~23:15

AFFIRMO - 老年衰弱、多病共存和多重用药患者房颤的综合方法AFFIRMO研究：房颤在衰弱、多病共存及多重用药老年人中的整合管理策略

格雷戈里·Yh·利普

PVI-SHAM-AF: 肺静脉隔离对比假手术（SHAM）治疗房颤PVI-SHAM-AF研究：肺静脉隔离对比假手术（SHAM）治疗房颤

罗尔夫·瓦赫特

NEXAF - 非持续性房颤患者的长期运动NEXAF研究：非持续性房颤患者的长期运动干预

比亚尼·内斯

IDEAL-AF: 个人化低电压消融在持续性房颤中的应用IDEAL-AF研究：持续性房颤中的个人化低电压区消融

阿斯特里德·保罗·诺丁

 

热线 9

北京时间：8月30日 23:30~00:30

SHASTA-3/4 12个月结果SHASTA-3/4研究：12个月结果

杰拉尔德·沃茨

CRHCP: 长期血压控制与痴呆风险CRHCP研究：长期血压控制与痴呆风险

孙英贤 中国医科大学附属第一医院

心血管风险谱系中的血压降低治疗跨不同心血管风险谱系的降压治疗

卡泽姆·拉希米

ECLIPSE-CKD: 慢性肾病中的代盐丹麦冠状动脉脱钙试验

东水 中国哈尔滨

 

热线 10

北京时间：8月31日 14:15~15:30

ASPIRED: 多中心开放标签随机对照试验，比较即刻强化门诊心电图监测与标准监测在急性不明原因晕厥患者中的效果ASPIRED研究：即时强化动态心电图监测对比标准监测在急性不明原因晕厥患者中的多中心开放标签随机对照试验

马修·詹姆斯·里德

DANISH-CRT: 针对心力衰竭双心室起搏的靶向左心室导线植入DANISH-CRT研究：靶向左心室导线植入用于心力衰竭双心室起搏

延斯·科塞迪斯·尼尔森

SyncAV PMT: Clinical Benefit of Dynamic AV Optimization in CRTSyncAV PMT研究：CRT中动态房室优化的临床获益

尼拉杰·瓦尔玛

Syncope-Stopper: Upfront Pacing vs Standard Care in High-Risk Unexplained SyncopeSyncope-Stopper研究：早期起搏对比标准治疗在高危不明原因晕厥中的应用

杰里米·威廉

HIS 替代方案 IIHIS 替代方案 II 研究

迈克尔·温特

 

热线 11

北京时间：8月31日 19:00~20:00

EVAOLD: 老年患者再灌注策略的评估EVAOLD研究：老年患者再灌注策略的评估

吉勒斯·巴拉内-罗谢特

ISOLEDS: IVUS vs OCT Guidance for PCI of Distal Left Main Bifurcation LesionsISOLEDS研究：IVUS对比OCT指导远端左主干分叉病变PCI

曾勇 首都医科大学附属北京安贞医院

CorCal研究：汇集队列方程对比冠状动脉钙化积分在ASCVD一级预防中的应用CorCal研究：汇集队列方程对比冠状动脉钙化积分在ASCVD一级预防中的应用

约瑟夫·B·穆尔斯坦

CoCAP研究：CABG术后接受DAPT或阿司匹林单药治疗的ACS患者桥血管通畅率

乔纳斯·霍尔姆

 

热线 12

北京时间：8月31日 20:15~21:15

DISCO试验：院外心脏骤停复苏成功后ECG无ST段抬高患者的急诊冠状动脉造影DISCO研究：院外心脏骤停复苏成功后ECG无ST段抬高患者的急诊冠状动脉造影

斯滕·鲁伯特松

CAG after OHCA without ST-elevation无ST段抬高的院外心脏骤停后行冠状动脉造影

伦特波尔

The HeartRunner Trial: Out-of-Hospital Cardiac Arrest Survival following Community First Responder activationHeartRunner研究：社区第一响应者激活后院外心脏骤停的生存率

弗雷德里克·福尔克

Prague 26: 导管定向溶栓治疗肺栓塞Prague 26研究：导管定向溶栓治疗肺栓塞

维克托·科查

LAACS-2. Left Atrial Appendage Closure with Surgery-2
LAACS-2研究：外科手术同期左心耳封堵-2

Helena Dominguez

 

 

02 LBS

Computed tomography first? Redefining the coronary care pathway

北京时间：8月28日 14:15~15:45

Initial Evaluation with Combined CT Perfusion and Angiography for Suspected NSTEMI: Impact on Invasive Coronary Angiography Utilization and Coronary Etiology Detection
对疑似NSTEMI患者行CT灌注与CT血管造影联合初始评估：对有创冠状动脉造影使用率及冠状动脉病因检出率的影响

高炜 中国

Coronary CT Angiography to Guide Lipid Management in an Asymptomatic Community-Based Population
冠状动脉CT血管造影用于指导无症状社区人群的血脂管理

郭翔 中国

在稳定性冠状动脉疾病患者诊断路径中增加CT衍生的血流储备分数：FUSION随机试验在稳定性冠状动脉疾病患者诊断路径中增加CT衍生的血流储备分数：FUSION随机试验

亚历山大·赫施

丹麦冠状动脉钙化病变干预试验

塞尔玛·哈西菲克

基于自动化深度学习算法检测的冠状动脉总粥样硬化体积在一般人群中的预测价值 - SCAPIS队列分析基于自动化深度学习算法检测的冠状动脉总粥样硬化体积在一般人群中的预测价值——SCAPIS队列分析

约翰·马尔姆奎斯特

冠状动脉CT血管造影用于优化经人工智能筛查的低风险患者有创冠状动脉造影的诊断阳性率冠状动脉CT血管造影用于优化经人工智能筛查的低风险患者有创冠状动脉造影的诊断阳性率

杰里米·佩奇

 

Late-Breaking Clinical Science: management of coronary microvascular disease

北京时间：8月28日 14:15~15:45

The Vericiguat in Vasospastic Angina (ViVA) trial: a double-blind placebo-controlled randomized cross-over study
Vericiguat治疗血管痉挛性心绞痛（ViVA）试验：一项双盲、安慰剂对照、随机交叉研究

Hanae Namba

ncremental diagnostic value of coronary microvascular dysfunction testing in patients with a working diagnosis of myocardial infarction with nonobstructive coronary arteries by stress CMR
负荷心脏磁共振诊断为MINOCA的患者进行冠脉微血管功能障碍检测的额外诊断价值

Jannike Nickander

Microvascular Resistance Reserve and Cardiovascular Outcomes: Prespecified Analysis of FLOW-CMD
微血管阻力储备与心血管结局：FLOW-CMD的预设分析

The DiagnOsis of MINOCA (DOMINO) registry: a real-world use of multimodality imaging and its impact on etiologic classification
MINOCA诊断（DOMINO）登记研究：多模态影像在真实世界中的应用及其对病因分类的影响

Doralisa Morrone

Head-to-head comparison of multiple cardiac magnetic resonance parameters for the detection of CMVD in patients with INOCA: Validation with integrated PET/MRI scanner
多项心脏磁共振参数用于检测INOCA患者中CMVD的头对头比较：以一体化PET/MRI扫描仪进行验证

CMR-Derived Epicardial Adipose Tissue Differentiates Etiologies and Predicts Outcomes in Patients With Suspected MINOCA
心脏磁共振衍生的心外膜脂肪组织可鉴别疑似MINOCA患者的病因并预测结局

陈文苏 徐州医科大学附属医院

 

Late-Breaking Clinical Science on heart failure: diagnosis and prognosis registries

北京时间：8月28日 17:00~18:00

Mortality and hospitalization rates in 19,397 participants according to ejection fraction phenotype and country income level: The Global Congestive Heart Failure Registry.
根据射血分数表型和国家收入水平分层的19,397名参与者的死亡率和住院率：全球充血性心力衰竭登记研究

Kelley Branch

ECG Flow ATTR: Artificial Intelligence Enabled Early Diagnosis of Transthyretin Cardiac Amyloidosis Using Electrocardiography
ECG Flow ATTR研究：基于心电图的人工智能辅助转甲状腺素蛋白心脏淀粉样变早期诊断

Seyed Reza Mirjalili

Personalised Evaluation of NT-proBNP and Clinical Characteristics in Suspected Heart Failure
疑似心力衰竭患者中NT-proBNP及临床特征的个体化评估

Kieran Docherty

Proactive screening identifies unrecognized heart failure after ST-elevation myocardial infarction
主动筛查可识别ST段抬高型心肌梗死后未被识别的心力衰竭

Chris Lenselink

 

Late-Breaking Clinical Science: valvular heart disease

北京时间：8月28日 19:45~21:00

EuroHeart - TAVI Registry
EuroHeart—TAVI登记研究

Rajesh Kharbanda

Optimal Medical Treatment With or Without Valve Repair in Patients with symptomatic Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: a multicenter, randomized comparison
有症状反常低流量、低跨瓣压差主动脉狭窄患者单纯优化药物治疗对比优化药物治疗加瓣膜修复：一项多中心随机对照研究

Julinda Mehilli

Efficacy and safety of routine post-dilatation using a balloon-expandable transcatheter aortic valve implantation platform - the randomized controlled DUOTAP trial.
球囊扩张式经导管主动脉瓣置入系统术后常规后扩张的疗效与安全性——DUOTAP随机对照试验

Maximilian Autherith

EMPagliflozin after Aortic Valve Replacement study: a randomized clinical trial
主动脉瓣置换术后恩格列净应用研究：一项随机临床试验

Louise Marqvard Soerensen

Prosthesis-Patient Mismatch after Transcatheter or Surgical Treatment of Aortic Valve Stenosis: A Sub-Study of the Randomized DEDICATE-DZHK6 Trial
经导管或外科手术治疗主动脉瓣狭窄后的瓣膜-患者不匹配：随机DEDICATE-DZHK6试验的亚组研究

Tobias Rheude

 

Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies

北京时间：8月28日 22:15~23:15

Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia
血管生成素样蛋白3抗体rivocibart治疗纯合子家族性高胆固醇血症

彭道泉 中南大学湘雅二医院

Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3
靶向ANGPTL3的CRISPR-Cas9基因编辑疗法CTX310的疗效持久性

Luke Joseph Laffin

AAV8-mediated gene therapy for homozygous familial hypercholesterolemia
AAV8介导的基因治疗用于纯合子家族性高胆固醇血症

Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study
单剂量Kylo-11后Lp(a)的极长持续时间降低：首次人体研究的最终数据

Ashish Sarraju

 

Late-Breaking Clinical Trials: global health

北京时间：8月29日 14:15~15:45

Long-term effectiveness of intensive blood pressure management led by non-physician community health-care providers on cardiovascular events: 7-year follow-up of a cluster randomised trial
非医生社区卫生保健提供者主导的强化血压管理对心血管事件的长期有效性：一项整群随机试验的7年随访结果

孙英贤 中国医科大学附属第一医院

A Multicomponent, Technology-Enabled Primary Care Intervention to Improve Cardiometabolic Risk Factors Control in Underserved Communities: The CHArMING Cluster-Randomized Trial
一项多组分、技术赋能的初级保健干预措施以改善医疗服务不足社区的心代谢危险因素控制：CHArMING整群随机试验

Clara Rodrigues Alves De Oliveira

Integrated Echocardiographic Screening for Rheumatic Heart Disease During Antenatal Care: A Cluster Randomized Crossover Trial
产前保健中整合超声心动图筛查风湿性心脏病：一项整群随机交叉试验

Thomas Pilgrim

SALT: A randomised controlled trial of potassium-enriched salt substitution in adolescents and their families in Soweto, South Africa
SALT研究：南非索韦托对青少年及其家庭进行富钾食盐替代的随机对照试验

Alta Schutte

Comparison of ESC and NICE Guidelines-recommended Initial Diagnostic Strategies in Patients with Stable Chest Pain: the OPERATE Randomized and Double-blinded Trial
ESC和NICE指南推荐的稳定性胸痛患者初始诊断策略比较：OPERATE随机双盲试验

周伽 天津市胸科医院

Prevention in Healthcare Professionals and the General Population: Insights from the ESC Congress 2025 Cardiovascular Health Check
医疗专业人员与普通人群的预防：来自2025年ESC大会心血管健康筛查的见解

Florian A Wenzl

 

Late-Breaking Clinical Science: pulmonary hypertension

北京时间：8月29日 17:00~18:00

Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE Outcomes Study
Ralinepag治疗改善结缔组织病相关肺动脉高压患者的预后：3期ADVANCE结局研究结果

Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial
左西孟旦用于射血分数保留的心力衰竭所致肺动脉高压患者：LEVEL试验结果

Sanjiv Shah

Automated Detection of Pulmonary Hypertension from a Single Apical Four-Chamber Echocardiographic Clip: development on the largest RHC-confirmed cohort to date and multinational external validation
基于单个心尖四腔心超声切面的肺动脉高压自动检测：在迄今为止最大的经右心导管确诊队列上开发并进行多国外部验证

Pulmonary Arterial Hypertension in Families with Hereditary Hemorrhagic Telangiectasia: A Nationwide Family Registry
遗传性出血性毛细血管扩张症家系中的肺动脉高压：一项全国性家系登记

周玉平 广东省人民医院

 

Late-Breaking Clinical Trials: optimising management of acute myocardial infarction

北京时间：8月29日 19:45~21:00

EnVast thrombectomy device as adjunctive reperfusion modality in ST-segment elevation myocardial infarction
EnVast血栓抽吸装置作为ST段抬高型心肌梗死的辅助性再灌注手段

Marco Valgimigli

Time-dependent effects of physiology-guided staged complete revascularisation in ST-segment elevation myocardial infarction with MVD disease: a multicentre, open -labelled, randomised STAGED trial
生理学指导的分步完全血运重建对合并多支血管病变的STEMI患者的时间依赖性效应：一项多中心、开放标签随机STAGED研究

王焱 厦门大学附属心血管病医院

Percutaneous coronary intervention using sirolimus eluting balloons in patients at high bleeding risk: Evidence from the SELUTION DeNovo trial
使用西罗莫司洗脱球囊对高出血风险患者行经皮冠脉介入治疗：SELUTION DeNovo试验证据

Tuomas Rissanen

Immediate Versus Deferred Percutaneous Coronary Intervention in Clinically Stable Patients with STEMI Presenting Beyond 12 Hours of Symptom Onset - The LATE-MI Randomized Trial
症状发作超过12小时就诊的临床稳定STEMI患者中，即刻与延迟经皮冠状动脉介入治疗的比较——LATE-MI随机试验

Lars Nepper-Christensen

Aspirin Discontinuation 1-month After PCI in Acute Myocardial Infarction: Individual-patient-data pooled analysis of the TARGET-FIRST and ULTIMATE-DAPT randomized trials
急性心肌梗死患者PCI术后1个月停用阿司匹林：TARGET-FIRST和ULTIMATE-DAPT随机试验的个体患者数据汇总分析

Giuseppe Tarantini

 

The evolution of atrial fibrillation ablation: energy, mapping and precision patient selection

北京时间：8月29日 19:45~21:00

Hybrid Versus Catheter Ablation for Persistent Atrial Fibrillation and Heart Failure: The HALT AF Randomised Trial
混合消融对比导管消融治疗持续性房颤合并心力衰竭：HALT AF随机试验

Omar Ahmed

Pulmonary Vein Isolation with Pulsed Field Ablation with versus without Posterior Wall Ablation in Patients with Symptomatic Persistent Atrial Fibrillation
有症状的持续性房颤患者中，脉冲场消融肺静脉隔离联合或不联合后壁消融的比较

Laurent Roten

Pulsed-Field Ablation With/Without Electrogram Mapping of Key Substrates for Non-paroxysmal Atrial Fibrillation: A Prospective Multicenter Randomized Study (PEAK-AF Study)
非阵发性房颤关键基质的脉冲场消融伴/不伴电图标测：一项前瞻性多中心随机研究（PEAK-AF研究）

12-month safety and effectiveness of a dual energy focal pulsed field ablation system to treat paroxysmal atrial fibrillation: results from the FlexPulse IDE study
双能量局灶脉冲场消融系统治疗阵发性房颤的12个月安全性和有效性：FlexPulse IDE研究结果

Ayman Hussein

AI-Guided Shared Decision-Making for Optimizing Patient Selection in Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial (AI-PAFA Trial)
人工智能辅助的共同决策优化房颤导管消融患者筛选：一项随机临床试验（AI-PAFA试验）

Taehyun Hwang

 

Late-Breaking Clinical Science: hypertrophic cardiomyopathy

北京时间：8月29日 22:15~23:15

Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial
Aficamten对有症状的非梗阻性肥厚型心肌病患者心脏结构和功能的影响——ACACIA-HCM试验结果

Sheila Hegde

Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM
Aficamten与美托洛尔单药治疗梗阻性肥厚型心肌病的比较：基于MAPLE‑HCM试验前治疗情况

Fernando Dominguez

Deep Learning Model for Detection, Phenotyping, and Left Ventricular Gradient Estimation in Hypertrophic Cardiomyopathy Using Echocardiography: Development and Multinational External Validation
基于超声心动图的深度学习模型用于肥厚型心肌病的检测、表型鉴定及左心室压差估计：开发与多国外部验证

Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE
玛伐凯泰治疗梗阻性肥厚型心肌病患者长达5年的安全性和有效性：MAVA-LTE最终结果

Anjali Owens

 

Digitalis glycosides in heart failure: back to the future!

北京时间：8月29日 23:30~00:30

Early or late, benefits of digoxin reconsidered in HFrEF: Insights from the Digitalis Investigation Group Trial (DIG)
无论早期还是晚期，重新审视地高辛在HFrEF中的获益：来自洋地黄研究组（DIG）试验的启示

Misato Chimura

Efficacy of digitoxin over time in patients with HFrEF: further analysis of DIGIT-HF
洋地黄毒苷在HFrEF患者中随时间变化的有效性：DIGIT-HF的进一步分析

Udo Bavendiek

Low-dose Digoxin in Women and Men with Heart Failure: Data from DECISION
低剂量地高辛用于男性和女性心力衰竭患者：DECISION研究数据

Dirk van Veldhuisen

Long-term cost-effectiveness of digitoxin in heart failure with reduced ejection fraction analyzed in DIGIT-HF
基于DIGIT-HF的洋地黄毒苷在射血分数降低的心力衰竭中的长期成本效果分析

Priyanka Boettger

 

Acute coronary syndromes: new strategies for diagnosis, risk stratification and early treatment

北京时间：8月29日 23:30~00:30

Modified HEART Score Triage With Point-of-Care hs-cTnI in Suspected ACS: Clinical Outcomes in the HARTc 2.0 Randomized Trial
改良HEART评分结合床旁高敏肌钙蛋白I对疑似ACS进行分诊：HARTc 2.0随机试验的临床结局

Anne Catherine Mh van der Lande

The Long-cTnT/hs-cTnT Ratio as a Novel Discriminator Between Takotsubo Syndrome and Acute Coronary Syndrome
Long-cTnT/hs-cTnT比值作为鉴别Takotsubo综合征与急性冠状动脉综合征的新型指标

Yujing Wang

A Clinical Decision Rule with High-Sensitivity Troponin to Rule Out Acute Coronary Syndrome in Primary Care (POB HELP): A Diagnostic Trial
初级保健中使用高敏肌钙蛋白排除急性冠脉综合征的临床决策规则（POB HELP）：一项诊断试验

Tobias N Bonten

Ischaemic Conditioning in High-Risk ST-elevation Myocardial Infarction: The Randomized, Multicentre, RIP-HIGH Trial
高危ST段抬高型心肌梗死中的缺血适应：RIP-HIGH随机多中心试验

Hans-Josef Feistritzer

 

Prevention in 2026: artificial intelligence, obesity and personalised cardiovascular care

北京时间：8月30日 14:15~15:45

The Personal Plaque Threshold: A Causal AI Biological World Model for Selecting Individualized LDL Targets to Personalize Cardiovascular Prevention
个体化斑块阈值：基于因果AI生物全域模型制定个体化LDL目标值，实现个体化心血管疾病预防

Brian A Ference

Risk of Ischemic Stroke With Beta-Blockers: Evidence From Randomized Clinical Trials
β受体阻滞剂与缺血性卒中风险：来自随机临床试验的证据

Franz Messerli

Cardiometabolic parameters by the degree of maintenance of weight reduction in tirzepatide-treated adults with obesity: post hoc study of SURMOUNT MAINTAIN Trial
替尔泊肽治疗的肥胖成人中体重减轻维持程度对心脏代谢参数的影响：SURMOUNT MAINTAIN试验的事后分析

Luke Joseph Laffin

High-Intensity Interval Training Reduces 10-Year Mortality in Older Adults: The Generation 100 Randomized Controlled Trial
高强度间歇训练降低老年人10年死亡率：Generation 100随机对照试验

Sindre Midttun

Machine learning and hemodynamic profile-based clinical decision support systems for personalized guideline-concordant antihypertensive treatment in primary care (LIGHT-precision)
用于初级保健中个体化且符合指南的降压治疗的基于机器学习与血流动力学特征的临床决策支持系统（LIGHT-precision）

郑昕 中国医学科学院阜外医院

BetaBlocker discontinuation in patients with chronic coronary syndrome, prior myocardial infarction: a pooled analysis of the ABYSS and SMART-DECISION randomised trials.
既往心肌梗死的慢性冠脉综合征患者停用β受体阻滞剂：ABYSS与SMART-DECISION随机试验的合并分析

Johanne Silvain

 

Late-Breaking Basic & Translational Science

北京时间：8月30日 14:15~15:45

Danicamtiv, a Novel Cardiac Myosin Activator, Is Associated with Improved Right Ventricular Function: pre-clinical and clinical evidence in patients with DCM
新型心肌肌球蛋白激动剂Danicamtiv与右心室功能改善有关：扩张型心肌病临床前及临床研究证据

Neal Lakdawala

Ambient Air Pollution Associates with Dose-Dependent Loss of the Y Chromosome via IL6R Inflammatory Signalling and Adverse Cardiovascular Outcomes: From 200,000 Men to Single Bone Marrow Cells
环境空气污染通过IL6R炎症信号与剂量依赖性的Y染色体丢失及不良心血管结局相关：从20万名男性到单个骨髓细胞

Wesley Abplanalp

Dynamic DPP3 profiling for rapid bedside risk stratification in acute myocardial infarction-related cardiogenic shock
动态DPP3检测用于急性心肌梗死相关心源性休克的床旁快速风险分层

Tharusan Thevathasan

Deciphering Reticulated Platelets Across Chronic and Acute Coronary Syndromes: Transcriptomic and Proteomic Evidence for S100A8/9-TLR4 Signaling dysregulation
解析慢性和急性冠脉综合征中的网织血小板：S100A8/9-TLR4信号失调的转录组学和蛋白质组学证据

Dario Bongiovanni

Fine-tuned mTORC1 inhibition preserves inflammatory signature in liver and heart to rescue HFpEF
精细调控mTORC1抑制可维持肝脏与心脏炎症特征以改善HFpEF

Christian Oeing

Macrophage RNASET2 is associated with activation of innate RNA-sensing program in heart failure with preserved ejection fraction
巨噬细胞RNASET2与射血分数保留的心力衰竭中先天免疫RNA感知程序的激活相关

Elijah Genetzakis

 

Late-Breaking Clinical Science: cardio-oncology

北京时间：8月30日 17:00~18:00

A RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
前列腺癌患者心血管及生活方式危险因素随机干预研究

Darryl Leong

An open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2 targeted therapy related cardiac dysfunction.
一项开放标签、随机对照试验，评估对已恢复的HER2靶向治疗相关心功能不全患者停用药物的安全性

Benjamin Dowsing

Incidence and Predictors of Arterial Thrombosis in Cancer Patients: The Prospective COMPASS-Arterial Cancer Associated Thrombosis (COMPASS-ARTeCAT) Study
癌症患者动脉血栓的发生率与预测因素：前瞻性COMPASS-动脉性癌症相关血栓（COMPASS-ARTeCAT）研究

Maria Drakopoulou

Heart Failure and Incident Hematologic Malignancies: A Nationwide Population-Based Cohort Study
心力衰竭与新发血液系统恶性肿瘤：一项全国性基于人群的队列研究

So-Young Lee

 

Late-Breaking Clinical Science: cardiac amyloidosis

北京时间：8月30日 19:45~21:00

A Phase 3 Clinical Trial of I124-evuzamitide to Diagnose Cardiac Amyloidosis
I124-evuzamitide诊断心脏淀粉样变的III期临床试验

Sharmila Dorbala

A Meta-Analysis of Gene Silencer Therapy in ATTR-CM
ATTR-CM中基因沉默治疗的荟萃分析

Julian Gillmore

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy
Vutrisiran在伴心肌病的转甲状腺素蛋白淀粉样变性中的疗效：按基线Tafamidis使用情况分析

Yasuhiro Hamatani

Efficacy and safety of transthyretin gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy receiving stabiliser therapy in the CARDIO-TTRansform trial
CARDIO-TTRansform试验中，转甲状腺素蛋白基因沉默剂eplontersen在接受稳定剂治疗的转甲状腺素蛋白淀粉样变性心肌病患者中的有效性和安全性

Pablo Garcia-Pavia

Effect of anselamimab on cardiac structure and function in patients with light chain amyloidosis: The CARES trials
Anselamimab对轻链淀粉样变性患者心脏结构和功能的影响：CARES试验

Xiaowen Wang

 

Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition

北京时间：8月30日 19:45~21:00

Effects of finerenone in patients with hypertensive nephropathy
非奈利酮在高血压肾病患者中的治疗作用

Hiddo Heerspink

Extended Follow-Up of the KARDINAL Trial Assessing the Effect of Tonlamarsen in Uncontrolled Hypertension
KARDINAL试验的延长随访：评估Tonlamarsen在未控制高血压中的疗效

Luke Joseph Laffin

Aldosterone suppression is more effective than blood pressure reduction in reversing cardiac remodelling due to primary aldosteronism: the MATCH and PATHWAY-1 prospective CMR sub-studies
在逆转原发性醛固酮增多症所致心脏重构方面，抑制醛固酮比降低血压更有效：MATCH和PATHWAY-1前瞻性CMR亚研究

James Morris Wilson

Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial
Baxdrostat在未控制或难治性高血压患者中的长期有效性和安全性：BaxHTN III期试验结果

Bryan Williams

Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
非奈利酮在慢性肾脏病伴心血管疾病患者中的有效性和安全性：个体参与者数据合并分析（INFINITY）

Carolyn S P Lam

 

Late-Breaking Clinical Science: optimising outcomes in heart failure

北京时间：8月30日 22:15~23:15

Randomised intravenous iron trials for heart failure: an individual-patient-data meta-analysis
静脉铁剂治疗心力衰竭的随机试验：一项患者个体化数据的荟萃分析

John Cleland

Effect of In-Hospital Initiation of Dapagliflozin on Decongestion-Related Endpoints in Acute Heart Failure: A Prespecified Analysis of the DAPA ACT HF-TIMI 68 Trial
住院期间启动达格列净对急性心力衰竭去充血相关终点的影响：DAPA ACT HF-TIMI 68试验的预设分析

Andre Small

Obesity, Frail Obesity, and Clinical Outcomes with a Fully Magnetically Levitated Left Ventricular Assist Device: the MOMENTUM 3 Trial
肥胖、虚弱性肥胖与全磁悬浮左心室辅助装置的临床结局：MOMENTUM 3试验

Milica Vukicevic

Evolving Trends in Treatments, Morbidity, and Mortality in Heart Failure: 30 Years of Data from the Italian Network of Heart Failure (IN-HF) Registry
心力衰竭治疗、发病率和死亡率的演变趋势：来自意大利心力衰竭网络（IN-HF）登记的30年数据

Aldo Pietro Maggioni

 

Late-Breaking Clinical Science: global cardiovascular health inequalities

北京时间：8月30日 23:30~00:30

Documenting the gap between current European practice in secondary prevention and the new ESC guidelines on cardiac rehabilitation: Principal results from the EUROASPIRE VI survey in 27 countries
记录当前欧洲二级预防实践与ESC心脏康复新指南之间的差距：EUROASPIRE VI在27个国家调查的主要结果

David Allan Wood

Global Patterns of Wealth-Related Cardiometabolic Care Cascade Inequalities and Their Impact on Predicted 10-Year Cardiovascular Risk
全球财富相关心血管代谢照护级联不平等的格局及其对预测10年心血管风险的影响

Bamba Gaye

Global patterns of blood pressure lowering and projected cardiovascular disease and mortality
全球降压模式及预测的心血管疾病和死亡率

Christina Magnussen

THe Sub-Saharan Africa Survey of Heart Failure II - Regional Perspectives
撒哈拉以南非洲心力衰竭调查II——区域视角

Simon Stewart

 

Late-Breaking Clinical Science: hypertension

北京时间：8月30日 23:30~00:30

Efficacy and safety of sacubitril/allisartan plus amlodipine in hypertensive patients not adequately controlled by amlodipine or sacubitril/allisartan monotherapy: the SALUS study
沙库巴曲/阿利沙坦联合氨氯地平在氨氯地平或沙库巴曲/阿利沙坦单药控制不佳的高血压患者中的有效性和安全性：SALUS研究

李建平 北京大学第一医院

The ELFIE-HYPERTENSION Trial: An international randomized multicenter trial of an artificial intelligence enhanced and gamified mobile health intervention for hypertension management
ELFIE-HYPERTENSION试验：一项关于人工智能增强和游戏化移动健康干预用于高血压管理的国际随机多中心试验

Karla Santo

Blood pressure management with an artificial intelligence-enhanced app and wearable devices: My Intelligent Cardiac Assistant (MICArdiac) Randomised Controlled Trial
基于人工智能增强的应用和可穿戴设备的血压管理：My Intelligent Cardiac Assistant（MICArdiac）随机对照试验

Chemical adherence testing-guided intervention is cost-effective in management of non-adherence to antihypertensive treatment - life-time evaluation of OUTREACH Study
化学依从性检测指导的干预在管理抗高血压治疗不依从方面具有成本效果——OUTREACH研究的终身评估

Luana Lenzi

 

Late-Breaking Clinical Trials: optimising atrial fibrillation ablation

北京时间：8月31日 14:15~15:45

Improving esophageal protection during AF ablation: a multicenter randomized controlled trial
改善房颤消融期间的食管保护：一项多中心随机对照试验

Viral A Sagar

Left atrial posterior isolation in addition to pulmonary vein isolation in patients with persistent AF refractory to pharmacologic cardioversion: The LEAP-AF randomized clinical trial
在药物复律无效的持续性房颤患者中，除肺静脉隔离外增加左心房后壁隔离：LEAP-AF随机临床试验

Keisuke Okawa

Additional Low-Voltage-Area ablation During Atrial Fibrillation Rhythm In Patients With Persistent Atrial Fibrillation: a prospective, randomized clinical trial
持续性房颤患者在房颤节律期间追加低电压区消融：一项前瞻性随机临床试验

朱雪峰 青岛大学附属烟台毓璜顶医院

A Randomised Controlled Trial of Ripple Mapping-guided isthmus ablation versus Local Activation Time-guided ablation in Atrial Tachycardia: The Ripple AT-plus study
Ripple Mapping引导的峡部消融与局部激动时间引导的消融治疗房性心动过速的随机对照试验：Ripple AT-plus研究

Balrik Kailey

A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint versus Prespecified Ablation Strategy Followed by Cardioversion in Patients with Persistent
以房颤终止作为手术终点的消融与预设消融策略后复律在持续性房颤患者中的随机对照研究

宋子良 上海交通大学附属胸科医院

The FLEX-PVI Trial: High-Power Short-Duration Pulmonary Vein Isolation Using a Flexible-Tip Contact Force-Sensing Catheter
FLEX-PVI试验：采用柔性尖端接触力感应导管的高功率短时程肺静脉隔离

Kenji Kuroki

 

Beyond statins: the next wave of lipid-lowering therapies

北京时间：8月31日 14:15~15:45

Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial
英克司兰与贝派地酸降低LDL-C的头对头比较：在高和极高心血管风险患者中的4期VICTORION-CHALLENGE试验结果

Ingo Hilgendorf

Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study
口服HRS-5346，一种新型小分子脂蛋白(a)抑制剂，在脂蛋白(a)升高且心血管高风险成人中的2期随机双盲研究

朱丹 北京大学第三医院

Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial
基于方案的急性冠脉综合征患者早期强化降脂管理（BRIDGE）：一项多中心前瞻性整群随机对照试验

Kazuma Oyama

A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)
一项评估vsa003注射液在中国青少年和成人纯合子家族性高胆固醇血症患者中有效性和安全性的III期临床试验

田庄 中国医学科学院北京协和医院

Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial
依洛尤单抗对既往无心肌梗死或卒中患者致死性结局的影响：VESALIUS-CV试验的预设分析

Robert Giugliano

Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)
靶向Lp(a)的长效siRNA类药物Lepodisiran对氧化磷脂的作用

Steven E Nissen

 

Transforming the heart: novel therapies for myocardial disease and heart failure

北京时间：8月31日 17:15~18:15

Outcomes of Intracoronary AAV1/SERCA2a Gene Therapy in Patients With Heart Failure With Preserved Ejection Fraction: 12-Month Results From the MUSIC-HFpEF Phase 1/2a Trial
冠脉内AAV1/SERCA2a基因治疗在射血分数保留的心力衰竭患者中的结局：MUSIC-HFpEF 1/2a期试验的12个月结果

Marat Fudim

CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy
CIRRUS-HCM：新型心脏肌节调节剂EDG-7500在非梗阻性和梗阻性肥厚型心肌病中的安全性和有效性的12周评估

Anjali Owens

The autoregulated bioprosthetic total artificial heart in advanced biventricular failure: 180-day outcomes from the EFICAS study
自动调节型生物人工全心脏在晚期双心室衰竭中的180天结局：EFICAS研究

Andre Vincentelli

Intravenous Dexrazoxane for Hemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial (SHIELD-MI)
静脉注射右雷佐生用于STEMI中出血性心肌梗死：一项双盲、安慰剂对照、序贯队列IIa期试验（SHIELD-MI）

Keyur Vora

 

Late-Breaking Clinical Science: pulmonary embolism

北京时间：8月31日 17:15~18:15

Predictors of treatment response in acute intermediate-risk pulmonary embolism: analysis from the HI-PEITHO randomized study
急性中危肺栓塞治疗反应的预测因素：来自HI-PEITHO随机研究的分析

Reperfusion Strategies for Intermediate-Risk Pulmonary Embolism: A Meta-analysis
中危肺栓塞的再灌注策略：一项荟萃分析

Ioannis Farmakis

An AI-driven Model to Improve Prediction of Early Mortality in Acute Pulmonary Embolism: The VITAL-PE Score
AI驱动模型提高急性肺栓塞早期死亡率预测：VITAL-PE评分

Romain Chopard

Rapid expansion of catheter-directed therapies for pulmonary embolism in Germany: A nationwide analysis of trends and outcomes
德国导管介入治疗肺栓塞的迅速扩展：一项全国性趋势与结局分析

Vera Oettinger

 

Heart failure: the kidney is key

北京时间：8月31日 19:00~20:00

Kidney Function Decline, Heart Failure Hospitalization and the Effect of Empagliflozin in Heart Failure: An EMPEROR-Pooled Analysis
肾功能下降、心力衰竭住院及恩格列净在心力衰竭中的疗效：EMPEROR汇总分析

Nicolas Girerd

Glomerular filtration rate slope as a surrogate endpoint for kidney disease progression in heart failure trials: An individual participant data meta-analysis
肾小球滤过率斜率作为心力衰竭试验中肾脏疾病进展的替代终点：个体参与者数据荟萃分析

Muthiah Vaduganathan

Predicting Short-term Effects on Blood Pressure, Kidney Function, and Serum Potassium with Heart failure Therapies and their Combinations
预测心力衰竭治疗及其联合方案对血压、肾功能和血清钾的短期影响

Nelson Wang

Precision Phenotyping of Multi-Organ Fat Distribution Defines Distinct Cardiorenal-Metabolic and Heart Failure Risk Profiles
多器官脂肪分布的精准表型分析定义了不同的心肾代谢和心力衰竭风险特征

 

Advances in stroke prevention: anticoagulation, antiplatelet therapy and left atrial appendage closure

北京时间：8月31日 19:00~20:00

Half-Dose Anticoagulation versus Standard Antiplatelet Therapy for Preventing Silent Cerebral Embolism After Left Atrial Appendage Occlusion: The HALO-SCE Randomized Trial
左心耳封堵术后半量抗凝 vs. 标准抗血小板预防隐匿脑栓塞的疗效：HALO-SCE随机试验

居维竹 南京医科大学第一附属医院

Dual antiplatelet therapy (DAPT) during the first 90 days post-randomisation in OCEANIC-STROKE: participant characteristics and interaction with asundexian
OCEANIC-STROKE研究中随机化后前90天的双联抗血小板治疗：参与者特征及与asundexian的交互作用

Mukul Sharma

Sex-Specific Outcomes of Left Atrial Appendage Closure Versus Medical Therapy: The CLOSURE-AF-DZHK-16 Trial
左心耳封堵术与药物治疗的性别特异性结局：CLOSURE-AF-DZHK-16试验

Left Atrial Appendage Closure as an Alternative to NOAC for Stroke Prevention in Patients with Atrial Fibrillation at Low Bleeding Risk: A Patient-Level Meta-Analysis
左心耳封堵作为低出血风险房颤患者卒中预防中NOAC的替代方案：一项患者水平荟萃分析

Megan Coylewright

 

Valvular heart disease: lessons from real-world practice

北京时间：8月31日 20:15~21:15

Primary Results of the VHD-W (Valvular Heart Disease in Women) Study
VHD-W（女性瓣膜性心脏病）研究的主要结果

Julia Grapsa

Medium-term outcomes following contemporary transcatheter aortic valve implantation in England: insights from national registry linkage
基于全国登记数据库关联分析的临床启示：英格兰现代经导管主动脉瓣植入术后的中期预后

Rajesh Kharbanda

Isolated Tricuspid Valve Replacement at 20-Year Follow-up. Insight from the largest multicenter international registry. DURABLE Tricuspid
孤立性三尖瓣置换术20年随访：来自最大规模国际多中心登记DURABLE Tricuspid的洞见

Edoardo Zancanaro

How Much Tricuspid Regurgitation Reduction Is Enough? Residual TR and Long-Term Outcomes After T-TEER in the Randomized TRI-FR Extension
需要减少多少三尖瓣反流才足够？TRI-FR延伸随机研究中T-TEER术后残余三尖瓣反流与长期结局

Erwan Donal

 

Late-Breaking Clinical Trials: atrial fibrillation detection to treatment strategies

北京时间：8月31日 20:15~21:15

Longer-term prognostic benefit of low-dose digoxin versus beta-blockers in patients with permanent atrial fibrillation and symptoms of heart failure
在永久性房颤伴心力衰竭症状患者中，低剂量地高辛对比β受体阻滞剂的长期预后获益

Dipak Kotecha

Ablate versus Pace in Elderly Patients With Persistent Atrial Fibrillation
老年持续性房颤患者中消融与起搏的比较

Joachim Ehrlich

Clinical Implications of Atrial Fibrillation Detection Using Wearable Devices in Patients With Cryptogenic Stroke (CANDLE-AF) Trial: Design and Rationale
可穿戴设备检测房颤在隐源性卒中患者中的临床意义（CANDLE-AF）试验：设计与理论依据

Sodam Jung

REAL-PATCH-AF: Real-world performance of self-applied ECG patch systems for atrial fibrillation screening in older adults: a randomized comparison of six systems
REAL-PATCH-AF：自贴式心电图贴片系统在老年房颤筛查中的真实世界性能——六种系统的随机比较

Daniel Pavluk

 

Better decisions in coronary revascularisation

北京时间：8月31日 20:15~21:15

Two-Year Outcomes of Intravascular Ultrasound Guided versus Angiography Guided Complex High-Risk Indicated Percutaneous Coronary Intervention
血管内超声引导与血管造影引导的复杂高危指征经皮冠状动脉介入治疗的两年结局

Roberto Diletti

Ticagrelor versus Prasugrel in Patients Undergoing Invasive Management of Coronary Artery Disease
替格瑞洛与普拉格雷在接受有创性冠状动脉疾病管理患者中的比较

Daniele Giacoppo

Long-term clinical outcomes in patients with angina and non obstructive coronary artery disease undergoing comprehensive invasive coronary function testing
心绞痛合并非阻塞性冠状动脉疾病且接受全面有创冠脉功能检测患者的长期临床结局

Peter Damman

Twenty-Year Outcomes of a Randomized Comparison between Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Unprotected Left Main Stem Stenosis
无保护左主干狭窄患者中经皮冠状动脉介入与冠状动脉旁路移植术随机比较的二十年结局

Steffen Desch

 

Late-Breaking Clinical Science: advanced cardiovascular imaging

北京时间：8月31日 20:15~21:15

Goal-Directed vs Self-Directed Valsalva Maneuver to Improve Patent Foramen Ovale Detection: The BUBBLE Randomized Crossover Trial
目标导向与自我导向Valsalva动作提高卵圆孔未闭检出率的比较：BUBBLE随机交叉试验

Tzlil Grinberg

Impact of stress CT myocardial Perfusion on downstream resources and PROgnosis in patients with suspected or known coronary artery disease: CTP-PRO Study results at 1-year follow-up
负荷CT心肌灌注对疑似或已知冠状动脉疾病患者后续资源利用和预后的影响：CTP-PRO研究1年随访结果

Gianluca Pontone

Novel 3-dimensional echocardiographic quantification of mitral regurgitant volume
新型三维超声心动图定量二尖瓣反流量

Carlo Federico Guarino

Using AI to detect atrial myopathy and predict cardioembolic stroke from routine cardiac CT: the ORFAN-MAESTRIA study
利用AI通过常规心脏CT检测心房肌病并预测心源性卒中：ORFAN-MAESTRIA研究

Charalambos Antoniades